Over the course of the past months, Halberd Corporation (OTCMKTS:HALB) has done a lot of work with regard to its research initiatives and due to the success that the company eventually found in that work, it has expanded the scope of the research.
Earlier on in the week, the company made another announcement with regards to the work that they had been doing regarding the elimination of C-Reactive protein from cerebral spinal fluid and that was another major breakthrough from Halberd. On April 4, the company announced that it had deployed its extracorporeal process for eliminating the above-mentioned protein by way of exposure to in vitro tuned laser light.
Not too long ago, the company had been in considerable focus after it had been successful in eliminating all the top ten antigens which cause CTE, PTSD, and other neurodegenerative conditions. Following the success of that operation, the company had decided to move into the elimination of C-Reactive protein, which is regarded as the major antigen that causes clinical depression in individuals. In this situation, it is necessary for investors to note that clinical depression and depression, in general, is an ever-growing problem in the United States.
As per statistics from the National Institute of Mental Health, major depression is currently among the most commonly occurring mental health conditions in the United States. The study further noted that an estimated 21 million people in the United States suffered from at least one episode of depression in 2020.
The number actually makes up as much as 8.4% of the population in the United States and hence, it could be said that a significant market opportunity exists for Halberd in the long run. At this point in time, it may be a good idea for investors to add the stock to their watch lists and keep an eye on further developments.
